dcc-3084
·Code: DCC-3084
dcc-3084: developed by 1 company · 1 clinical trial tracked.
dcc-3084 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect dcc-3084 to DCPH; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could dcc-3084 → DCPH affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) Advanced Solid Tumor | Phase 1/Phase 2 |
Clinical Trials (1)
A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Primary endpoint: Number of Participants with Dose-limiting Toxicities (DLTs) (ModA Part 1)
Interventionalopen29 targetStarted 2024-05Completion 2026-029 sites · United StatesDeciphera Pharmaceuticals, LLC
Frequently asked questions
Who is developing dcc-3084?
dcc-3084 is being developed by Deciphera Pharmaceuticals, Inc..
How many clinical trials involve dcc-3084?
BioSniper tracks 1 clinical trial involving dcc-3084.